专注于创新药自主研发的生物医药企业必贝特(688759.SH)拟于科创板IPO上市

Group 1 - The core point of the news is that Bibet (688759.SH) has released its IPO prospectus for listing on the Sci-Tech Innovation Board, planning to issue 90 million shares, which will account for approximately 20.00% of the total share capital post-issuance [1] - The initial strategic placement will involve 18 million shares, representing 20.00% of the total issuance, with the final strategic placement amount to be determined after the pricing on October 15, 2025 [1] - Bibet focuses on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to creating First-in-Class drugs and addressing unmet clinical needs [1] Group 2 - As of the signing date of the prospectus, the company has one Class 1 innovative drug, BEBT-908, approved for market, while BEBT-209 is in Phase III clinical trials, and BEBT-109 has been approved to start Phase III trials, with five products in Phase I trials [2] - The net proceeds from the IPO, after deducting issuance costs, will be allocated to various projects: 949 million yuan for new drug research and development, 555 million yuan for the construction of the Qingyuan R&D center and formulation industrialization base, and 500 million yuan for working capital [2]